908 Devices INC 8-K filings

908 Devices Inc. announced second quarter 2026 financial results, reporting a 23% year-over-year revenue increase and narrowing its Adjusted EBITDA loss, while also raising its full-year revenue guidance.

908 Devices Inc. has issued over 3.2 million shares to satisfy earnout obligations related to its acquisition of RedWave Technology.

908 Devices Inc. shareholders re-elected three Class III directors and ratified the appointment of PricewaterhouseCoopers LLP at the 2026 Annual Meeting.

908 Devices Inc. has acquired NIRLAB AG, a Swiss company specializing in AI-powered near-infrared (NIR) spectroscopy for narcotics identification, for an upfront consideration of $15 million.

908 Devices Inc. announced robust fourth quarter and full year 2025 financial results, achieving positive Adjusted EBITDA in Q4 and providing a positive 2026 revenue outlook.

908 Devices Inc. announced strong preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025, achieving positive Adjusted EBITDA in Q4.

908 Devices Inc. reported third quarter 2025 financial results, with year-to-date revenue up 16% and an improved Adjusted EBITDA loss, while reiterating its full-year revenue outlook.

908 Devices Inc. reported a 14% increase in second-quarter 2025 revenue from continuing operations and raised its full-year 2025 revenue guidance.

908 Devices Inc. announced the appointment of Dr. Brandi Vann, a former U.S. Department of Defense leader, to its Board of Directors, following the resignation of Jeff George.

908 Devices Inc. announced the appointment of co-founder Christopher D. Brown to its Board of Directors, filling the vacancy left by Marcia Eisenberg's resignation, which was not due to any disagreement with the company.

908 Devices Inc. announced that its stockholders approved the election of all Class II directors and ratified the appointment of PricewaterhouseCoopers LLP as its independent auditor at the 2025 Annual Meeting.

908 Devices' first quarter 2025 revenue grew 59% year-over-year, fueled by an 86% increase in handheld product and service revenue.

908 Devices finalizes the sale of its desktop device portfolio to Repligen Corporation and releases pro forma financial statements reflecting the transaction.

908 Devices divested its desktop portfolio to Repligen for $70 million, reported a 31% increase in fourth-quarter revenue, and initiated a revenue outlook for 2025.

Repligen Corporation has acquired 908 Devices' desktop portfolio of bioprocessing process analytical technology (PAT) devices for $70 million in cash.

908 Devices reported a 17% year-over-year revenue increase for Q3 2024, alongside announcing a restructuring and manufacturing transition to improve efficiency and reduce costs.

908 Devices Inc. has released an updated investor presentation and highlighted its various communication channels for disseminating company information.

908 Devices announced a 16% year-over-year revenue increase for the second quarter of 2024, primarily driven by strong growth in its handheld product line and the acquisition of RedWave Technology.

908 Devices Inc. has finalized its acquisition of RedWave Technology and filed an amended 8-K report including historical financials and pro forma information.

908 Devices has appointed Michele M. Leonhart, former Administrator of the U.S. Drug Enforcement Administration, to its Board of Directors, effective immediately.

908 Devices Inc. successfully held its 2024 Annual Meeting of Stockholders, electing two Class I directors and ratifying PricewaterhouseCoopers LLP as its independent auditor.

908 Devices announced a 5% increase in revenue for Q1 2024, driven by strong handheld device sales, and the acquisition of RedWave Technology to expand their forensics product portfolio.

908 Devices has acquired RedWave Technology, a provider of portable FTIR spectroscopic analyzers, to expand its portfolio of handheld chemical analysis devices.

908 Devices saw a 23% increase in revenue for the fourth quarter of 2023, driven by a 57% surge in handheld device sales, while providing a 2024 revenue outlook of 4% to 8% growth.